Corvus Pharmaceuticals (CRVS) Assets (2015 - 2026)

Corvus Pharmaceuticals' Assets history runs 12 years deep, the most recent figure standing at $253.2 million for Q1 2026.

• On a quarterly basis, Assets rose 325.98% year-over-year to $253.2 million in Q1 2026; TTM through Mar 2026 was $253.2 million, a 325.98% increase from a year earlier, with the FY2025 full-year figure at $71.1 million, up 3.21% from the prior year.
• Assets improved to $253.2 million in Q1 2026 per CRVS's latest filing, from $71.1 million in the prior quarter.
• Across five years, Assets topped out at $253.2 million in Q1 2026 and bottomed at $40.1 million in Q1 2024.
• The 5-year median for Assets is $68.2 million (2022), against an average of $79.0 million.
• Across the five-year window, Assets tumbled 42.54% in 2023 and soared 325.98% in 2026, its largest moves.
• Year by year, Assets stood at $68.2 million in 2022, then slumped by 33.25% to $45.6 million in 2023, then surged by 51.27% to $68.9 million in 2024, then grew by 3.21% to $71.1 million in 2025, then jumped by 256.02% to $253.2 million in 2026.
• Per Business Quant, the three latest CRVS Assets figures stand at $253.2 million (Q1 2026), $71.1 million (Q4 2025), and $80.5 million (Q3 2025).